Launch of 2 new generic treatments - Zydus Lifesciences Ltd

Code BSE: 532321 NSE:

a) ZyVet Launches First Generic Treatment for Canine Urinary Incontinence b) ZyVet launches affordable Furosemide tablets to support long-term heart care trusted diuretic for dogs and cats now available in a generic form Speaking on this development, Punit Patel, President and CEO, Zydus Americas, said “Urinary incontinence affects quality of life for both pets and their families. Our phenylpropanolamine hydrochloride tablets deliver on both clinical reliability and affordability, enabling veterinarians to confidently treat more patients and maintain client compliance. We’re proud to offer an option that removes cost as a barrier to compassionate care. With each launch, we reinforce that innovation doesn’t need to come with a premium price tag – and that every pet should have access to high-quality treatment options.”